| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2002 | CN1077891C 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-HT4 or H3 receptor ligands |
| 01/16/2002 | CN1077890C 4-aminoethyoxy-indolone derivatives as dopamine D2 agonists |
| 01/16/2002 | CN1077889C Piperazine derivatives and their use as 5-HT1A antagonists |
| 01/16/2002 | CN1077888C Benzopyrans and pharmaceutical compsn. contg. same |
| 01/16/2002 | CN1077887C Method for preparing antihypertensive and anticancer compound |
| 01/16/2002 | CN1077886C Amidino derivatives useful as nitric oxide synthase inhibitors |
| 01/16/2002 | CN1077885C Biphenylsulfonamide matrix metalloproteinase inhibitors |
| 01/16/2002 | CN1077799C prevention of retinal injury and degeneration by specfic factors |
| 01/16/2002 | CN1077792C Pyridylbisphosphonates for use as therapeutical agent |
| 01/16/2002 | CN1077791C Artificial snake bile and its mfg. method |
| 01/16/2002 | CN1077790C Agent for treating gluaucoma and agent for reducing eye pressure |
| 01/15/2002 | USRE37516 Acetamide derivative having defined particle size |
| 01/15/2002 | US6339160 For therapy of tumoral growth and metastatization, aterosclerosis, multiple sclerosis, alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases |
| 01/15/2002 | US6339154 (2-Substituted oxyphenyl) alkanamide derivative, hair growth promoter and external composition for skin using the same |
| 01/15/2002 | US6339151 Forming compounds using a nucleic acid base with a phosphorous halide to form drugs for nonproliferation of cells |
| 01/15/2002 | US6339139 Receptor-mediated gene transfer system for targeting tumor gene therapy |
| 01/15/2002 | US6339107 Methods for treatment of Emphysema using 13-cis retinoic acid |
| 01/15/2002 | US6339106 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 01/15/2002 | US6339105 Gradually increasing dosage of tramadol administered to reduce side effects |
| 01/15/2002 | US6339104 Therapeutic agent for primary biliary cirrhosis |
| 01/15/2002 | US6339102 Method and composition for treating and preventing retinal damage |
| 01/15/2002 | US6339101 Administering n-linked sulfonamide of an n-heterocyclic carboxylic acid derivative for therapy of nerve-related vision disorder, improving vision, therapy memory impairment or enhancing memory performance in an animal |
| 01/15/2002 | US6339100 Methods for inhibiting mastocytosis |
| 01/15/2002 | US6339098 2,1-benzisothiazoline 2,2-dioxides |
| 01/15/2002 | US6339097 N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them |
| 01/15/2002 | US6339095 Therapeutic use of 1, 6-dimethyl-8β-hydroxymethyl-10-α-methoxyergoline |
| 01/15/2002 | US6339094 2-acylaminopropanamines as tachykinin receptor antagonists |
| 01/15/2002 | US6339093 For therapy of neurodegeneration; used as nmda(n-methyl-d-aspartate)-receptor subtype selective blockers |
| 01/15/2002 | US6339092 Metalloprotease inhibitors |
| 01/15/2002 | US6339088 Composition for treatment of external secretion disorders except hypol acrimation |
| 01/15/2002 | US6339086 Administering n-desmethylzopiclone, or its pharmaceutically acceptable salt, solvate, hydrate, or clathrate for prophylaxis or therapy of anxiety |
| 01/15/2002 | US6339085 For therapy of hypertrophy, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, heart failure subsequent to myocardial infarction, myocardial infarction, ischemia reperfusion injury, blood coagulation |
| 01/15/2002 | US6339083 Multiheterocyclic pharmAceuticals |
| 01/15/2002 | US6339082 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same |
| 01/15/2002 | US6339080 Iron compounds, compositions, methods of making the same and uses thereof |
| 01/15/2002 | US6339079 Steroid sulfamates, method for the production and use thereof |
| 01/15/2002 | US6339078 Administering an estrogen compound over a course that includes a first dose within 12 hours after the ischemic event, the estrogen compound being administered subcutaneously in an oil-based vehicle to achieve sustained delivery |
| 01/15/2002 | US6339077 Substituted 4-benzylaminoquinolines and their hetero analogs, process for their preparation, pharmaceuticals containing these compounds and use thereof |
| 01/15/2002 | US6339076 Therapeutic food composition and method to diminish blood sugar fluctuations |
| 01/15/2002 | US6339075 Use of dextran and other polysaccharides to improve mucus clearance |
| 01/15/2002 | US6339074 Sulfated hyaluronic acid and esters thereof |
| 01/15/2002 | US6339073 Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases |
| 01/15/2002 | US6339072 Compositions and methods for preventing restenosis following revascularization procedures |
| 01/15/2002 | US6339071 For preventing proliferation of tumor cells |
| 01/15/2002 | US6339070 Gene directed enzyme prodrug therapy (gdept) using in situ antibody generation to provide enhanced selectivity, in cancer therapy; for delivering cytotoxic drugs |
| 01/15/2002 | US6339063 9a-azalides as veterinary antimicrobial agents |
| 01/15/2002 | US6338963 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 01/15/2002 | US6338862 Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
| 01/15/2002 | US6338859 Polymeric micelle compositions |
| 01/15/2002 | US6338851 Method of suppressing an immune response to a transplanted organ or tissue by administering an OX-2 protein |
| 01/15/2002 | US6338843 Polysaccharide dextrin bonded to doxorubicin |
| 01/15/2002 | CA2199995C Use of 2,4-diamino pyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders |
| 01/15/2002 | CA2164411C Process for the isolation of lovastatin |
| 01/15/2002 | CA2160132C Use of steroid antagonists for the therapy and prophylaxis of demential illnesses |
| 01/15/2002 | CA2109304C Glycosylated prodrugs, and their processes of preparation and use |
| 01/15/2002 | CA2099195C Vitreous humor tamponade for the posterior cavity in an eye |
| 01/15/2002 | CA2094727C Hydrogen-containing chlorofluorocarbon aerosol medicaments |
| 01/15/2002 | CA2094726C Non-chlorofluorocarbon aerosol formulation comprising a particulate medicament |
| 01/15/2002 | CA2090479C Stock solution of sucralfate suspended in water and production thereof |
| 01/15/2002 | CA2067243C Compositions and methods for weight reduction |
| 01/15/2002 | CA2059725C Diluent for perfluorocarbons employed for retinal unfolding (unfolding pfcl) |
| 01/15/2002 | CA2057055C Method of treating catabolic, gut-associated pathological processes and impaired host defenses |
| 01/15/2002 | CA2054209C Antihyperlipidemic and antiatherosclerotic urea compounds |
| 01/15/2002 | CA2039826C Spiro bridged and unbridged heterocyclic compounds |
| 01/15/2002 | CA2028302C Benzimidazole derivatives, their production and use |
| 01/14/2002 | CA2352496A1 Oral solid pharmaceutical formulations with ph-dependent multiphasic release |
| 01/13/2002 | CA2312051A1 Methylated nucleotide regulation of gene expression |
| 01/12/2002 | CA2352605A1 Formulations containing non-substitute flavylium-salt-type compounds in position 3 for skin colouring and uses |
| 01/11/2002 | CA2352618A1 Vitamin- and mineral-salt-based formulation for reducing loss and/or promoting regrowth of hair |
| 01/10/2002 | WO2002003684A2 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| 01/10/2002 | WO2002002812A2 Method for determining the susceptibility to stoke by analysing the ins gene |
| 01/10/2002 | WO2002002797A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 01/10/2002 | WO2002002772A2 Human extracellular matrix (ecm)-related tumor marker |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002645A1 COLD WATER SOLUBLE β-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 01/10/2002 | WO2002002607A2 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | WO2002002606A2 Immunisation against chlamydia pneumoniae |
| 01/10/2002 | WO2002002595A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | WO2002002593A2 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| 01/10/2002 | WO2002002589A1 Novel antiandrogenic agent |
| 01/10/2002 | WO2002002587A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | WO2002002584A1 Base analogues |
| 01/10/2002 | WO2002002572A1 Ruthenium (ii) compounds for use in the therapy of cancer |
| 01/10/2002 | WO2002002567A1 Thienopyrrolidinones |
| 01/10/2002 | WO2002002566A1 Therapeutic compounds and methods |
| 01/10/2002 | WO2002002565A2 Glucocortiocoid-selective antiinflammatory agents |
| 01/10/2002 | WO2002002564A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | WO2002002563A2 Substituted-triazolopyrimidines as anticancer agents |
| 01/10/2002 | WO2002002560A2 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| 01/10/2002 | WO2002002558A1 Pyrroloquinolones as antiviral agents |
| 01/10/2002 | WO2002002554A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | WO2002002553A1 Pharmaceutical compositions for treatment of diabetic nephropathy |
| 01/10/2002 | WO2002002552A1 Quinazoline ditosylate salt compounds |
| 01/10/2002 | WO2002002551A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | WO2002002549A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/10/2002 | WO2002002548A1 Coumarin derivatives with comt inhibiting activity |
| 01/10/2002 | WO2002002547A1 Pyrones as inhibitors of cyclooxygenase-2 |
| 01/10/2002 | WO2002002543A1 Method for producing a phenothiazine granulate with improved properties |
| 01/10/2002 | WO2002002541A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002539A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |